View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
February 14, 2020

Evgen and Rochester University partner to advance SFX-01 trial

Evgen Pharma has signed a memorandum of understanding (MoU) with the University of Rochester School of Medicine & Dentistry to advance SFX-01 towards a clinical study for treating patients with chronic kidney disease (CKD).

Evgen Pharma has signed a memorandum of understanding (MoU) with the University of Rochester School of Medicine & Dentistry to advance SFX-01 towards a clinical study for treating patients with chronic kidney disease (CKD).

The CKD disorder is caused by kidney dysfunction and is also known as chronic kidney failure.

Evgen’s SFX-01 product is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.

Under the agreement, Evgen will supply SFX-01 to support a potential future clinical trial led by University of Rochester Nephrology division chief Thu Le.

According to the company, the intention of the study is to investigate SFX-01 in a randomised controlled trial to see if the treatment can decrease kidney disease progression rate.

The trial will also investigate whether SFX-01 can decrease markers of oxidative stress and inflammation in CKD patients.

Thu Le said: “We are pleased that Evgen will support our plans to undertake a clinical trial on SFX-01 in patients with CKD.

“Increased oxidative stress is a major molecular underpinning of CKD progression and our research suggests that patients with the GSTM1 null allele may particularly benefit from sulforaphane treatment via SFX-01 dosing.’”

Evgen noted that the study will test whether patients with the null allele of the Glutathione S-Transferase M1 (GSTM1) gene respond better compared to that of placebo-administered patients.

The GSTM 1 gene is part of the glutathione-S-transferase (GST) family regulated by Nrf2, which SFX-01 is said to activate.

Evgen Pharma CEO Stephen Franklin said: “We are delighted to be supporting the work of such a respected team and prestigious university.

“We very much hope the proposed trial will generate data demonstrating that SFX-01 could potentially improve the lives of patients suffering from CKD.”

In March last year, Evgen Pharma announced positive headline results from the open-label Phase II STEM trial of SFX-01 to treat patients with estrogen-positive (ER+) metastatic breast cancer.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena